Flutemetamol (18F)

Flutemetamol (¹⁸F)

Systematic (IUPAC) name
2-[3-(18F)Fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
Clinical data
Trade names	Vizamyl
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	Intravenous
Identifiers
ATC code	V09AX04
PubChem	CID 15950376
ChemSpider	13092196
UNII	0F3M7032P5
ChEBI	CHEBI:76611
Chemical data
Formula	C14H1118FN2OS
Molecular mass	273.316 g/mol
SMILES CNC1=C(C=C(C=C1)C2=NC3=C(S2)C=C(C=C3)O)[18F]
InChI InChI=1S/C14H11FN2OS/c1-16-11-4-2-8(6-10(11)15)14-17-12-5-3-9(18)7-13(12)19-14/h2-7,16,18H,1H3/i15-1 Key:VVECGOCJFKTUAX-HUYCHCPVSA-N

Flutemetamol (¹⁸F) (trade name Vizamyl, by GE Healthcare) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18, used as a diagnostic tool for Alzheimer's disease.^[1]

Mechanism of action

After the substance is given intravenously, it accumulates in beta amyloid plaques in the patient's brain, which thus become visible via positron emission tomography (PET).^[1]

References